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Abstract
Background: The tissue factor (TF)-dependent extrinsic pathway has been suggested to be a central mechanism
by which the coagulation cascade is locally activated in the lungs of patients with acute lung injury and acute
respiratory distress syndrome (ALI/ARDS) and thus represents an attractive target for therapeutic intervention. This
study was designed to determine the pharmacokinetic and safety profiles of ALT-836, an anti-TF antibody, in
patients with ALI/ARDS.
Methods: This was a prospective, randomized, placebo-controlled, dose-escalation Phase I clinical trial in adult
patients who had suspected or proven infection, were receiving mechanical ventilation and had ALI/ARDS (PaO2/
FiO2 ≤ 300 mm). Eighteen patients (6 per cohort) were randomized in a 5:1 ratio to receive ALT-836 or placebo,
and were treated within 48 hours after meeting screening criteria. Cohorts of patients were administered a single
intravenously dose of 0.06, 0.08 or 0.1 mg/kg ALT-836 or placebo. Blood samples were taken for pharmacokinetic
and immunogenicity measurements. Safety was assessed by adverse events, vital signs, ECGs, laboratory,
coagulation and pulmonary function parameters.
Results: Pharmacokinetic analysis showed a dose dependent exposure to ALT-836 across the infusion range of 0.06
to 0.1 mg/kg. No anti-ALT-836 antibody response was observed in the study population during the trial. No major
bleeding episodes were reported in the ALT-836 treated patients. The most frequent adverse events were anemia,
observed in both placebo and ALT-836 treated patients, and ALT-836 dose dependent, self-resolved hematuria,
which suggested 0.08 mg/kg as an acceptable dose level of ALT-836 in this patient population.
Conclusions: Overall, this study showed that ALT-836 could be safely administered to patients with sepsis-induced
ALI/ARDS.
Trial registration: ClinicalTrials.gov: NCT01438853
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Background
Acute lung injury (ALI) and acute respiratory distress
syndrome (ARDS) are major causes of acute respiratory
failure in patients of all ages, resulting in high rates of
morbidity and mortality despite decades of clinical
research. ALI/ARDS is characterized by diffuse alveolar
damage leading to disruption of the alveolar capillary
barrier, pulmonary edema and neutrophilic inflamma-
tion. Extravascular intra-alveolar thrombin formation
and fibrin deposition, often evident as hyaline mem-
branes lining the denuded alveolar surface, have long
been recognized as pathological hallmarks of ALI/ARDS.
These findings suggest that the coagulation cascade and
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ance, are altered in patients with ALI/ARDS [1-4].
The tissue factor (TF)-dependent extrinsic pathway has
been suggested as a central mechanism by which the coa-
gulation cascade is locally activated in the lungs of
patients with ALI/ARDS. TF is a transmembrane glyco-
protein normally expressed on subendothelial cells in the
vascular adventitia layer that is not in contact with the
circulating blood [5]. Vessel injury or pathological condi-
tions leading to the exposure TF in the vascular adventi-
tia layer or induction of TF expression on endothelial
cells and monocytes permits interactions between TF
and coagulation factor VIIa (FVIIa) resulting in the for-
mation of the high affinity TF-FVIIa complex. This com-
plex then binds factor × (FX), converting it to the
activated form FXa, which ultimately leads to thrombin
formation and fibrin deposition [6]. TF-FVIIa complexes
a l s op l a yar o l ei nc e l ls i g n a ling events mediated by the
TF cytoplasmic domain and by activation of the protease
activated receptors (PARs) either directing or via down-
stream TF-dependent coagulation proteases [1,7,8].
These signaling events stimulate proinflammatory cyto-
kines, growth factors and chemokines, some of which
further upregulate TF expression.
A direct role of TF in promoting ALI/ARDS has been
suggested based on elevated levels of TF observed in
plasma and pulmonary fluid of ALI/ARDS patients com-
pared to control subjects [9-11]. These higher plasma TF
levels correlated with the presence of disseminated intra-
vascular coagulation and sepsis in patients with ALI/
ARDS, and were associated with prolonged use for
mechanical ventilation and increased mortality. Immuno-
histochemistry of the lung tissue from patients with ALI/
ARDS showed prominent TF expression by alveolar
epithelial cells as well as intra-alveolar macrophages and
hyaline membranes [9], suggesting an active role of intra-
alveolar TF in fibrin deposition within the lungs of these
patients.
Consequently, development and evaluation of TF
antagonists has been of interest as a therapeutic strategy
for treating ALI/ARDS [1-3]. ALT-836 is a recombinant
IgG4 chimeric antibody that binds to human TF or the
TF-FVIIa complex preventing the association and activa-
tion of FX, thereby inhibiting thrombin generation [12].
The results of a preclinical study in a baboon model of
established E. coli-induced sepsis demonstrated that ALT-
836, administered after the onset of the disease, was able
to reverse the course of sepsis-induced lung and organ
injury by reducing abnormalities in gas exchange, pulmon-
ary hypertension, lung compliance and other clinically
relevant parameters [13]. Additionally, ALT-836 has been
administered to subjects with stable coronary artery dis-
ease (CAD) where it exhibited dose-dependent anticoagu-
lant effects [14]. Based on these preclinical and clinical
findings, we hypothesized that ALT-836 could serve as a
potential therapeutic agent for the treatment of sepsis-
induced ALI/ARDS. In this randomized, placebo-con-
trolled, dose-escalation Phase I clinical trial, we evaluated
the safety and pharmacokinetics of ALT-836 in critically
ill patients with sepsis-induced ALI/ARDS.
Methods
Patient selection
In this randomized, placebo-controlled, assessor-blinded,
dose-escalation Phase I clinical trial (ClinicalTrials.gov:
NCT01438853), seventeen ICUs (13 United States, 4
Canada) received institutional review board approval to
conduct the study and eight of these sites enrolled at
least one patient. Study enrollment occurred between
December 2004 and July 2006. Informed consent was
received by each patient or his/her legal surrogate prior
to enrollment. Eligible patients were at least 18 years of
age, had suspected or proven infection, were receiving
mechanical ventilation (≤ 48 h) and had ALI/ARDS.
Diagnostic criteria for ALI/ARDS included all of the fol-
lowing: acute bilateral pulmonary infiltrates on a chest
x-ray consistent with the presence of pulmonary edema,
a ratio of arterial oxygen tension to fraction of inspired
oxygen (PaO2/FiO2) of 100 to 300 mm Hg for ALI/
ARDS, and the clinical absence of left atrial hypertension.
The maximum period of sepsis induced ALI/ARDS prior
to study drug infusion was 48 hours. Exclusion criteria
included the following: platelet count < 50,000/mm
3, pro-
longed prothrombin time (PT) (INR > 3) or activated
partial thromboplastin time (aPTT) (> 2 × ULN), signifi-
cant potential for disseminated intravascular coagulation
or increased risk of bleeding (2 or more measurements of
prolonged aPTT (> 1.5 × ULN), fibrinogen level < LLN,
presence of petechiae, ecchymoses, or other evidence of
coagulopathy) (see Additional file 1: Table A1 for com-
plete inclusion/exclusion criteria).
Intervention
Based on the safety profile of ALT-836 observed in a
dose-escalation Phase I study in patients with stable
CAD [14], this clinical trial was originally designed with
five dosing cohorts (0.06, 0.1, 0.2, 0.3, and 0.4 mg/kg) of
ALT-836 with six subjects in each cohort. Patients were
to be randomized in a 5:1 ratio to receive ALT-836 or
placebo, respectively, administered as a single intrave-
nous bolus infusion over 15 minutes. Cohorts were
enrolled sequentially. Patients were then followed for a
28-day period post study drug administration. Following
the observation of adverse events (hematuria) in the 0.1
mg/kg dose group, the Data Safety Monitoring Board
(DSMB) recommended including an additional 5:1 ran-
domized dose group of 0.08 mg/kg ALT-836 or placebo
administered through an intravenous infusion over 2
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to determine if there is a relationship between maxi-
mum serum concentration of ALT-836 (Cmax)a n d
occurrence of adverse events. The protocol was
amended and the final study treatment groups included
A L T - 8 3 6d o s e da t0 . 0 6( 5p a t i e n t s ) ,0 . 0 8( 5p a t i e n t s ) ,
and 0.10 mg/kg (5 patients) and placebo (3 patients).
Patient assessments
Blood samples were collected prior to administration of
the study drug and subsequently post drug administra-
tion at 15 and 30 min, 1, 4, 6 (8 hr in 0.08 mg/ml
cohort), 12 and 24 hrs, daily thereafter through day 7
and weekly through day 28 for measurement of coagula-
tion, hematology and serum chemistry parameters and
serum levels of ALT-836. Serum samples for detection
of anti-ALT-836 antibodies were obtained pre-dose and
at 2 and 4 weeks post dosing. Safety assessments per-
formed during this study included investigator reported
adverse events, routine laboratory parameters including
blood gas measurements and chest x-rays, vital signs
measurements, physical examinations (baseline and 1, 7,
and 28 days post dosing) and electrocardiograms. Addi-
tional assessments included evaluating surrogate para-
meters for resource utilization (i.e.I C Ul e n g t ho fs t a y ,
ventilation free days, etc.).
Assay methods
Plasma samples for quantification of coagulation para-
meters were stored at -70°C until assayed at a central
laboratory. Standard PT assays using recombinant human
TF (RecombiPlasTin; Beckman Coulter, Miami, FL) or
rabbit brain thromboplastin (PT-Fibrinogen HS; Beckman
Coulter) and standard aPTT assays were conducted to
assess the activity of plasma coagulation factors. PT-
derived fibrinogen assays were performed using Recombi-
PlasTin reagent. Thrombin generation was evaluated
based on levels of prothrombin fragment 1 + 2 (F1+2) and
D-dimer assessed by a commercially available enzyme
linked immunosorbent assay (ELISA) (Dade Behring,
Deerfield, IL) and an antibody-coated latex agglutination
assay (Beckman Coulter), respectively.
Concentration of ALT-836 in serum samples was
determined using a validated sandwich ELISA, as
described previously [14]. Serum titer of anti-ALT-836
antibodies of different isotypes, if present, was deter-
mined by a validated bridging ELISA method employing
plate-bound ALT-836 as a capture reagent and HRP-
labeled ALT-836 as a detection reagent.
Study endpoints and stopping rules
The endpoints of this study were to evaluate the safety
and pharmacokinetics of ALT-836 in patients with sus-
pected or proven sepsis-induced ALI/ARDS. Major
bleeding was defined as any of the following occurring
within 2 weeks of infusion of ALT-836: intracranial
hemorrhage; clinically overt or occult bleeding requiring
surgical intervention; or transfusion of four or more
units of packed red blood cells over a 48-hour period.
Minor bleeding was defined as clinically overt or occult
bleeding that did not meet the definition of major bleed-
ing. Predefined stopping rules included early study ter-
mination pending DSMB review/recommendation if
major bleeding occurred in two patients infused with
ALT-836 within a cohort and study termination or dose
modification if one ALT-836 treated patient experienced
a major bleeding event.
Statistical analysis
All randomized patients received study drug or placebo
as planned and analysis was conducted on an intent-to-
treat basis. Safety, pharmacokinetic and other data were
grouped by study treatment and dose level. Safety vari-
ables were tabulated and presented for all patients who
received ALT-836 or placebo. Non-compartmental meth-
ods (WinNonlin 5.0, Pharsight Corp., Mountain View,
CA) were used to determine the pharmacokinetic para-
meters. Continuous variables were expressed as mean ±
SD and were compared using Student’s t test or the Wil-
coxon rank sum test, where appropriate. Testing for an
association between the dose of ALT-836 and bleeding
was performed using a c
2 test for trend. Analysis of the
variance was used to assess changes in variables from
baseline following study drug administration. A two-
sided P value of less than 0.05 was considered statistically
significant. All P values are unadjusted for multiple
testing.
Results
Baseline characteristics of the 18 patients enrolled in
this Phase I clinical trial are shown in Table 1. Of these
patients, one patient of the 0.08 mg/kg ALT-836 cohort
died (acute hypoxia, unrelated to study drug) during the
study, with the remaining patients completing the
28-day follow-up period.
Pharmacokinetics and immunogenicity
Study drug-treated patients of the first two cohorts
received 0.06 mg/kg or 0.1 mg/kg ALT-836 as a single
bolus intravenous infusion over 15 minutes, whereas the
third cohort received 0.08 mg/kg ALT-836 through a
2 hr infusion at 50 cc/hr. Pharmacokinetic analysis
showed a dose dependent exposure to ALT-836 across
the infusion range of 0.06 to 0.1 mg/kg (Table 2). Thus,
increasing the duration of infusion to 2 hrs for the 0.08
mg/kg dose group did not decrease Cmax or overall
exposure levels (AUCINF) as these values remained lin-
ear with dose. The terminal elimination half-life for
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values ranging from 18.5 to 22.6 hrs. Volumes of distri-
bution were about 50 ml/kg, consistent with plasma
volume in the vasculature.
There was no detectable serum anti-ALT-836 anti-
body activity in any of the ALT-836-treated patients
(n = 15).
Adverse events
Four patients encountered non-fatal serious adverse
events (SAEs) during the study, including bilateral pul-
monary embolism (0.06 mg/kg ALT-836-treated patient),
hypoxic respiratory failure (0.1 mg/kg ALT-836-treated
patient), worsening acute renal failure (placebo-treated
patient), and worsening anemia and empyema (placebo-
treated patient).
Of the 18 subjects enrolled in this trial, 16 subjects
reported a total of 87 adverse events (AEs) during the
study. Of these, 35 (40%) were mild in intensity, 48 (55%)
were moderate in intensity, and 4 (5%) AEs were severe
in intensity. The investigators attributed 16 of these AEs
as “related to study treatment” (2 in placebo group, 3 in
0.06 mg/kg ALT-836; 6 in 0.08 mg/kg ALT-836, and 5 in
0.1 mg/kg ALT-836 groups). A summary of the incidence
of treatment emergent AEs is presented Table 3 and a
detailed listing of the AEs is provided in Additional file 2:
Table A2.
The most frequent AE reported in patients treated with
ALT-836 was hematuria or worsening hematuria (n = 9)
(Table 3). These AEs were rated as mild to moderate and
assessed by the clinical investigator as possibly or prob-
ably related to study drug in 8 of the 9 patients. On aver-
age, hematuria started 6.7 hours after study drug
administration (range 3 - 19 hr), and resolved by 29.1
hours (range 6-53 hrs) post-onset without the need of
medical intervention. No patient with hematuria became
hemodynamically unstable and there was no decrease in
platelet counts, prolongation of PT and aPTT time or
increase in serum D-dimer and F1+2 levels. There was
also no significant difference in markers of renal function
(BUN, creatinine) between patients with or without
hematuria and no signs of capillary fragility (petechiae,
ecchymoses, conjunctival bleeding) were observed during
the duration of hematuria. Besides hematuria, no major
bleeding or other spontaneous minor bleeding events
were observed in any patient receiving ALT-836.
Table 1 Baseline characteristics
Characteristics Placebo
(n = 3)
0.06 mg/kg ALT-836
(n = 5)
0.08 mg/kg ALT-836
(n = 5)
0.10 mg/kg ALT-836
(n = 5)
Age, yr 49.7 ± 24.3 40.4 ± 18.2 54.0 ± 16.9 54.6 ± 13.7
Male, n (%) 1 (33.3) 1 (20.0) 2 (40.0) 0 (0.0)
Baseline APACHE II Score 22.7 ± 14.2 20.2 ± 5.5 20.0 ± 3.1 19.2 ± 5.1
Baseline respiratory variables
PO2/FIO2 226 ± 51 205 ± 65 221 ± 64 200 ± 48
Respiratory rate, bpm 28.7 ± 4.2 20.3 ± 6.9 20.60 ± 3.3
a 19.8 ± 7.2
pH 7.34 ± 0.09 7.35 ± 0.07 7.44 ± 0.04 7.39 ± 0.06
PEEP, cm H2O 10.0 ± 5.0 10.3 ± 5.6 10.4 ± 6.2 9.2 ± 4.1
Baseline coagulation & hematology variables
Prothrombin time, sec 17.0 ± 2.4 12.1 ± 1.5 14.8 ± 1.9 13.9 ± 0.3
aPTT, sec 32.9 ± 0.3 29.1 ± 2.5 31.1 ± 1.8 29.2 ± 1.7
Platelets, 10
6/ml 238 ± 115 256 ± 105 357 ± 309 244 ± 43
Hemoglobin, g/dl 10.7 ± 0.3 9.5 ± 1.2 10.0 ± 1.4 10.0 ± 1.8
APACHE II, Acute Physiology and Chronic Health Evaluation; PEEP, Positive end-expiratory pressure; aPTT, activated partial thromboplastin time
Values are means ± SD unless otherwise noted
a P < 0.05 compared to placebo group
Table 2 Pharmacokinetic parameters
0.06 mg/kg ALT-836 0.08 mg/kg ALT-836 0.1 mg/kg ALT-836
t1/2 term., hour 18.5 ± 5.9 22.6 ± 3.1 22.6 ± 6.2
Cmax, ng/ml (nM) 1,300 ± 560 (8.6) 1,490 ± 340 (9.9) 1,800 ± 250 (12.0)
Vd, ml/kg 46.1 ± 13.1 47.7 ± 16.0 54.5 ± 6.6
Cl, ml/hr/kg 1.9 ± 1.0 1.5 ± 0.7 1.8 ± 0.4
AUCINF, hr·ng/ml 39,000 ± 24,200 59,900 ± 20,500 59,900 ± 16,600
t1/2 term., terminal half-life; Cmax, maximum serum concentration; Vd, volume of distribution; Cl, total body clearance: AUCINF, area under the drug concentration
versus time curve extrapolated to infinity
Values are means ± SD
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as well as in two of three patients receiving placebo
(Table 3). These adverse events were assessed as study
drug related in 3 of 6 ALT-836-treated patients and in
both of the placebo treated patients, one of which (as
noted above) experienced anemia as a serious adverse
event.
Aside from these events, there were no other adverse
events or serious adverse events judged to be related to
ALT-836 treatment by the clinical investigators.
Assessment of clinical laboratory measurements and
patient outcomes
There was no significant treatment effect on PT, platelet
counts, aPTT, or plasma levels of D-dimer, prothrombin
fragment F1 + 2 or fibrinogen at any ALT-836 dose. At
the dose levels administered, the ALT-836 concentration
observed in the patients’ plasma were previously shown
to be insufficient to prolong PT driven by the large
excess of TF reagent added in the standard PT assay,
though inhibition of clot formation and thrombin gen-
eration was observed in a whole blood assay [14]. Addi-
tionally, treatment with high levels of a different TF
antagonist reportedly did not alter levels of either coa-
gulation factors or markers of thrombin generation in
patients with ALI/ARDS [15]. Thus, these laboratory
parameters of coagulation may not be useful in assessing
the pharmacodynamic effects of TF-targeted therapies.
As part of the safety assessment, evaluation of oxygena-
tion index and patient outcomes was conducted. There
was no significant treatment effect at any dose of ALT-
836 on PO2/FIO2 ratio while patients were on mechani-
cal ventilation. Assessment of hospital resource indices
also did not reveal significant differences in ventilation
free days or duration of hospital stay following ALT-836
treatment, though patients receiving 0.1 mg/kg ALT-836
showed an improvement in ICU-free days at day 28
when compared to placebo treated patients (mean ± SD:
8.7 ± 8.1 (placebo) vs. 20.0 ± 2.4 (ALT-836), P =0 . 0 3 6 )
(Table 4). Although this result is encouraging, it should
be noted that this study was not sufficiently powered to
assess ALT-836 efficacy and that because of the large
inherent variation in outcome parameters observed in
this patient population, preliminary evaluation of efficacy
end points will likely require a placebo-controlled Phase
II trial with at least 45 subjects per treatment arm [16].
T h eo v e r a l lm o r t a l i t yr a t eo b s e r v e di nt h i ss t u d yw a s
lower than that reported in recently published studies in
ALI/ARDS subjects [15]. However, this also likely reflects
the small number of subjects in this study since ongoing
follow-up studies with larger numbers of the same sub-
ject population verified that placebo-treated subjects
have a mortality rate consistent with historic values (H.
Wong, personnel communication).
Discussion
In a number of pre-clinical models, blockade of TF is
capable of preventing mortality during systemic infection
and inflammation, inhibiting endothelial cell injury
induced by anoxia-reoxygenation and permeability of
endothelial cells during systemic inflammation, reducing
lung and renal fibrin deposition, and limiting prolifera-
tion, migration and invasion of malignant cells [13,17,18].
In humans, TF levels are elevated in plasma and pulmon-
ary fluid of ALI/ARDS patients compared to control sub-
jects [9-11]. Taken together, these findings suggest that
TF may represent an important therapeutic target for
treatment of systemic inflammatory diseases such as
ALI/ARDS [1,2]. However, bleeding-related complica-
tions resulting from therapeutic inhibition of TF activity
remain a major concern. This was recently illustrated in
a Phase II clinical trial in ALI/ARDS patients where
administration of the TF-FVIIa complex inhibitor, active
site inactivated FVIIa (FVIIai), resulted in a dose-
depended increase in major bleeding events (3.8% for the
low dose to 17% for the highest dose) and an increased
28-day mortality rate [15]. In contrast to the FVIIai
s t u d y ,w ef o u n dt h a tA L T - 8 3 6 ,a na n t i b o d y - b a s e dT F
antagonist, was well tolerated by ALI/ARDS patients with
no drug-related deaths or major bleeding event observed
following treatment with dose levels from 0.06 to 0.1 mg/
kg. A similar safety profile (i.e. no serious bleeding or
drug-related SAEs) for ALT-836 at a single dose levels up
to 0.3 mg/kg was observed in 26 patients with CAD who
Table 3 Adverse events by treatment group
Placebo 0.06 mg/kg ALT-836 0.08 mg/kg ALT-836 0.10 mg/kg ALT-836 Total
(n = 3) (n = 5) (n = 5) (n = 5) (n = 18)
Mortality by study day 28 (treatment related) 0 (0) 0 (0) 1 (0) 0 (0) 1 (0)
Patients with non-fatal SAEs (treatment related) 2 (1
a) 1 (0) 0 (0) 1 (1
b) 5 (2)
Total number of AEs (treatment related) 20 (2) 18 (3) 29 (5) 20 (6) 87 (16)
Patients with hematuria AEs (treatment related) 0 (0) 2 (2) 2 (2) 5 (4) 9 (8)
Patients with anemia AEs (treatment related) 2 (2) 1 (1) 2 (2) 3 (0) 8 (5)
a Worsening anemia and empyema reported as possible related to placebo treatment
b Hypoxic respiratory failure (study day 23) secondary to hospital-acquired pneumonia reported as possible related to study drug treatment
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In the trial reported here, there was an ALT-836 dose-
dependent increase in mild to moderate hematuria
observed in some patients that typically started 6 to 8
hours after study drug administration and spontaneously
resolved approximately 24 hours post onset. These minor
bleeding episodes did not result in hemodynamic
instability and were not associated with alterations in
renal function or coagulation parameters. Interestingly,
analysis of the pooled data of ALT-836-treated patients
did not show a correlation between hematuria and higher
ALT-836 serum levels or exposure. Thus, it is possible
that other clinical confounders, including baseline/pre-
vious history of hematuria or concurrent use of urinary
catheters, influenced the development of hematuria fol-
lowing ALT-836 administration.
The dose levels of ALT-836 administered, while rela-
tively low in comparison to those of other therapeutic
antibodies, appear to be within the range required to inhi-
bit disease-associated TF activity. In the current study, the
results of pharmacokinetic analysis indicate that ALT-836
administered at 0.06 mg/kg to 0.1 mg/kg provided a maxi-
mum serum concentration of 9 to 12 nM, respectively.
In vitro studies have demonstrated that these ALT-836
concentrations are sufficient to inhibit > 90% of TF cofac-
tor activity at a broad range of TF concentrations (0.005-
2.3 nM) [12]. It is noteworthy that disease-associated,
elevated TF levels found in undiluted pulmonary edema
fluid of patients with ALI/ARDS ranged from 0.5 and
2 nM, approximately 100-fold higher than plasma TF
levels of the same patients [9]. Similarly higher levels of
TF-dependent procoagulant activity in bronchoalveolar
lavage (BAL) fluid of ARDS patients was observed three
days after clinical recognition of ARDS and decreased
thereafter [11]. Thus one would expect that ALT-836 at
dose levels tested in the present study when administered
shortly after diagnosis of ALI/ARDS should provide suffi-
cient antibody to block pulmonary and intravascular TF
activity for several days. Although ALT-836 levels were
not measured in patient’s pulmonary fluid of patients, we
have previously shown that the antibody could be readily
detected at the expected nanomolar level in BAL fluid col-
lected from baboons in a sepsis-induced organ failure
model [13], suggesting that ALT-836 is capable of distri-
buting between the vascular and alveolar compartments.
The pharmacokinetic analysis also revealed differences in
the antibody half-life between patients with ALI/ARDS
and CAD. Serum ALT-836 levels typically displayed expo-
nential decay kinetics with a terminal half-life of about 21
hours in ALI/ARDS patients, whereas a biphasic decay
with an initial plateau phase and a median 72 hour term-
inal half life was observed in patients with stable CAD
[14]. While patient management may have affected the
antibody pharmacokinetics, it is possible that elevated
levels of the TF antigen in the vascular and pulmonary
compartments of the ALI/ARDS patients contributed to
the observed increase rate of serum ALT-836 clearance.
Such antigen-antibody interactions have been reported to
play a role in the elimination kinetics of a variety of other
therapeutic antibodies [19].
The abundant evidence of extensive cross-talk between
the coagulation and the inflammatory systems have led
to numerous but unsuccessful studies utilizing anti-
thrombotic and fibrinolytic agents for treatment of ALI/
ARDS and sepsis [15,16,20-24]. Although most of these
agents are classified as anti-coagulants, they are known
to have other physiological functions in addition to their
anti-thrombotic activities. For example, activated protein
C (APC) not only regulates the coagulation pathway by
inactivating factor VIIIa and factor Va which decreases
thrombin mediated inflammation, but also binds to the
endothelial cell protein C receptor to inhibit endotoxin-
induced intracellular calcium fluxes and NF-B nuclear
translocation. These effects influence gene expression
profiles, inhibit leukocyte chemotaxis and adhesion to
activated endothelium, and inhibit endothelial cell apop-
tosis [25-29]. By stimulating cell signaling, APC can mod-
ulate the cellular response to infectious insults leading to
anti-inflammatory, cytoprotective and barrier-protective
properties which may contribute significantly to APC
Table 4 Hospital indices by treatment group
Placebo 0.06 mg/kg ALT-836 0.08 mg/kg ALT-836 0.1 mg/kg ALT-836
Days on ventilator 25.5 ± 25.7 14.1 ± 23.1 15.5 ± 10.4 6.4 ± 2.6
Days in ICU 29.2 ± 26.5 15.2 ± 22.1 16.4 ± 10.1 7.1 ± 2.4
Days in hospital 33.3 ± 29.1 29.9 ± 45.6 25.4 ± 12.6 16.7 ± 10.5
ICU free days at SD28
a 8.7 ± 8.1 17.4 ± 9.8 8.4 ± 9.0 20.0 ± 2.4
c
Ventilator free days at SD28
b 11.0 ± 9.8 18.8 ± 10.6 8.4 ± 11.2 21.0 ± 3.1
Values are means ± SD
a Mean number of days to study day 28 (SD28) that the patients were not admitted to the ICU. Patients that did not survive to SD28 were assigned zero ICU free
days
b Mean number of days to SD28 that the subjects were achieved unassisted breathing. Patients that did not survive to SD28 were assigned zero ventilator free
days
c P < 0.05 compared to placebo group
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alone or in complex with FVIIa, has also been shown to
exhibit many physiological effects in systemic inflamma-
tion, which differ from those of many anti-coagulants
including APC. Besides its role in triggering the coagula-
tion pathway, the TF-FVIIa complex per se activates
PAR2, which plays a crucial role in inflammatory
responses, fibrosis and tissue remodeling [31,32]. In a
mouse model, activation of PAR2 in the lung resulted in
airway constriction, pulmonary edema and increased
lung vascular and epithelial permeability [33]. Lung
PAR2 activation also induced acidosis, hypoxemia, hyper-
capnia and increase leukocyte infiltration, suggesting that
PAR2 activation can trigger a variety of inflammatory
responses associated with lung injury [33]. Similarly,
recent studies provide evidence that TF/FVIIa-mediated
FXa activation in the lung drives fibrotic responses via a
PAR1-dependent signaling mechanism [34,35]. Conse-
quently, the effectiveness of anti-coagulants as anti-
inflammatory agents may be largely dependent on the
relevance of particular pro-inflammatory signaling pro-
cesses at the systemic and local levels under different
pathological conditions. Thus, the enthusiasm for
employing novel anti-coagulants as therapeutic
approaches for ALI/ARDS should not be tempered by
the lack of clinical effectiveness of a particular anti-coa-
gulant in the treatment of these inflammation-associated
debilitating diseases.
Conclusions
Identification of an increased incidence of hematuria at
the 0.10 mg/kg dose level supported an acceptable safe
dose of ALT-801 at 0.08 mg/kg in patients with sepsis-
induced ALI/ARDS in this Phase I trial. Pharmacoki-
netic analysis indicated that ALT-836 administrated at
0.06 to 0.1 mg/kg could provide sufficient serum anti-
body levels to inhibit elevated TF activity reported in
ALI/ARDS patients. Taken together, these results sug-
gest that evaluation of the clinical activity of this anti-
body in patients with ALI/ARDS is warranted. Thus, a
follow-up randomized, double-blind, placebo-controlled
trial with a target enrollment of 150 patients is currently
being conducted to further assess the safety and efficacy
of single and multiple dose ALT-836 treatment in
patients with sepsis-induced ALI/ARDS (ClinicalTrials.
gov ID: NCT00879606).
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